Three tickers for capital gains

How I've Profited 4 Times While Others Chase AI Dreams ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View in browser Editor's Note: After Congress passed the "One Big Beautiful Bill Act" we reached out to our friend Nick Buhelos from Prime Corporate Services to help our readers explain what this bill means for traders... And tomorrow (Thursday, August 7) @ 4 p.m. ET, he is hosting a LIVE training breaking down how traders can protect their profits under the new tax bill. Click here to RSVP - Ryan Fitzwater, Publisher "I'm Trading the Patterns While Everyone Else Chases Miracles." Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance Dear Reader, Most people see a biotech AI stock and think "moon or bust." I see a pattern. While everyone's gambling on whether AbSci's artificial intelligence will cure cancer or crash and burn, I've been quietly trading the same range four different times this year for profit. Here's what I know about ABSI that the moon-shot crowd doesn't: This stock trades between $2.50 and $4.50. Period. I've done this dance all year, and I keep showing up to collect. The AI Biotech Reality Check AbSci uses artificial intelligence to develop new drugs. Sounds revolutionary, right? Maybe it is. Maybe it isn't. What I know for certain is that they're an early-stage company burning cash on clinical trials and AI development. No revenue from actual drug sales yet. Just hope, potential, and major company investments keeping the lights on. Every time there's news—good results, partnership announcements, whatever—the stock rockets higher. Then reality sets in. They need more cash for operations, so they do another secondary offering below market price, and down we go again. Rinse and repeat. That's the pattern. The Reason Elon’s Moving on From Tesla? A rogue venture capitalist is revealing what Elon’s up to… and now he’s giving away a FREE ticker symbol so investors can get pre-IPO exposure. 👉 [This is a limited opportunity, then this video is coming down - click here!] The $2.90 Setup Nobody's Talking About Right now, ABSI is sitting near $2.90 after their latest secondary offering drama. They recently raised $15 million between $3.00 and $3.25. Classic biotech move: Get everyone excited, pop the stock, then immediately dilute shareholders with discounted shares to fund operations. But here's what the complainers miss—this creates our entry opportunity. The Covered Call Sweet Spot Instead of betting everything on AI drug discovery miracles, I'm using covered calls to generate returns while we wait for the next move. The Trade: Buy ABSI stock at current levels Sell November $4 calls against the position Target net debit: $2.60-$2.65 The Math: At a $2.65 net cost, we make money if ABSI is above $2.65 at November expiration. That's it. If it runs to $4 by November, we get called away and make about 50% in a few months. If it stays flat around $3, we still profit from the time decay on the calls we sold. If it crashes back to $2.50, we're only down 15 cents from our cost basis instead of the 45 cents someone who bought at $2.95 would lose. Why This Beats the Hype Game Look, ABSI might eventually develop some miracle drug using AI. Or it might burn through investor cash for years like most biotechs do. I don't need to predict the future of artificial intelligence drug discovery. I just need to trade the pattern. This stock has shown me the same behavior four times this year. Each time, patient entry points and covered call strategies generated profits while the buy-and-holders rode the roller coaster. Position Sizing Reality Check: Nothing in my portfolio except income-generating positions exceeds 4% allocation. This is speculation money, not retirement money. ABSI has tremendous beta and backing from major companies, but it's still burning cash on unproven technology. Size accordingly. YOUR ACTION PLAN Range trading ABSI is just one type of opportunity we exploit in Catalyst Cash-Outs LIVE. While the crowd chases AI hype and earnings surprises, we're systematically trading the patterns they ignore. Ready to stop gambling on hope and start profiting from what actually works? Join Catalyst Cash-Outs LIVE and see exactly how we do it. INSIGHTS YOU MAY HAVE MISSED This Setup has "Explosion" Potential 3 Questions That Will Transform Your Trading Results What to Do When All Hell is Breaking Loose CAPE Ratio at 38.81 (This Is Not a Drill) This Stock has So Much Potential... it's MYTHICAL It's not dainty... or girly... or colorful. And it doesn't smell nice. But this stock has such one-of-a-kind profit potential... I call it a unicorn. It's so key to our economy, Trump once publicly went to bat for it. See why HERE>>>>> Monument Traders Alliance, LLC You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2025 Monument Traders Alliance, LLC | All Rights Reserved       Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.